Loading…
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $71M | $-337M | $-343M | $-277M | -58.1% | 23359.9% | 26.9% |
| 2024 | $0M | $-267M | $-270M | $-233M | -55.9% | -3.8% | 13.6% |
| 2023 | $0M | $-236M | $-238M | $-185M | -100.9% | -82.3% | 83.0% |
| 2022 | $2M | $-129M | $-130M | $-95M | -51.4% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1.77 | 0.31 | 0.30 | 70.85 |
| Operating Revenue | - | 1.77 | 0.31 | 0.30 | 70.85 |
| Operating Expense | - | 136.08 | 254.76 | 299.34 | 434.24 |
| Research And Development | - | 100.89 | 159.76 | 238.25 | 338.93 |
| Selling General And Administration | - | 35.18 | 95 | 61.08 | 95.32 |
| Total Expenses | - | 136.08 | 254.76 | 299.34 | 434.24 |
| Operating Income | - | -134.30 | -254.45 | -299.04 | -363.40 |
| Total Operating Income As Reported | - | -134.30 | -254.45 | -299.04 | -363.40 |
| EBITDA | - | -129.13 | -235.88 | -267.21 | -337.19 |
| Normalized EBITDA | - | -129.13 | -235.88 | -267.21 | -337.19 |
| EBIT | - | -129.39 | -236.40 | -267.75 | -337.65 |
| Interest Income | - | 4.92 | 18.24 | 31.60 | 27.40 |
| Interest Expense | - | 0.49 | 1.33 | 2.20 | 4.95 |
| Net Interest Income | - | 4.43 | 16.91 | 29.40 | 22.45 |
| Other Non Operating Income Expenses | - | - | -0.19 | -0.31 | -1.66 |
| Other Income Expense | - | - | -0.19 | -0.31 | -1.66 |
| Interest Income Non Operating | - | 4.92 | 18.24 | 31.60 | 27.40 |
| Interest Expense Non Operating | - | 0.49 | 1.33 | 2.20 | 4.95 |
| Net Non Operating Interest Income Expense | - | 4.43 | 16.91 | 29.40 | 22.45 |
| Pretax Income | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Net Income From Continuing And Discontinued Operation | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Net Income From Continuing Operation Net Minority Interest | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Net Income | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Net Income Common Stockholders | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Net Income Including Noncontrolling Interests | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Normalized Income | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Diluted NI Availto Com Stockholders | - | -129.87 | -237.73 | -269.95 | -342.60 |
| Basic Average Shares | - | 32.09 | 44.76 | 67.89 | 84.80 |
| Diluted Average Shares | - | 32.09 | 44.76 | 67.89 | 84.80 |
| Reconciled Depreciation | - | 0.26 | 0.52 | 0.54 | 0.46 |
| Total Unusual Items | 0 | - | - | - | - |
| Total Unusual Items Excluding Goodwill | 0 | - | - | - | - |
| Special Income Charges | 0 | - | - | - | - |
| General And Administrative Expense | - | 35.18 | 95 | 61.08 | 95.32 |
| Other Gand A | - | 35.18 | 95 | 61.08 | 95.32 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Viridian Therapeutics, Inc.this co. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Pulse Biosciences, Inc. | PLSE | $1.9B | -25.62 | 23.12 | -90.2% | -23.61 |
| Zymeworks Inc. | ZYME | $1.8B | -22.76 | 6.88 | -30.2% | -22.40 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B | -14.08 | 8.67 | -61.6% | -13.48 |
| Pediatrix Medical Group, Inc. | MD |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.8B |
| 11.11 |
| 2.12 |
| 19.1% |
| 7.64 |
| Vericel Corporation | VCEL | $1.8B | 110.33 | 5.14 | 4.7% | 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Nuvation Bio Inc. | NUVB | $1.8B | -8.80 | 5.89 | -66.9% | -8.95 |
| Rapport Therapeutics, Inc. | RAPP | $1.8B | - | -178.20 | -23.0% | - |
| Peer Median | - | -8.80 | 5.51 | -26.6% | -8.95 | |